COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
-
Page/Page column 279
(2019/04/26)
BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
Page/Page column 305; 306
(2017/02/09)
4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES
The invention relates to compounds of formula (I) wherein R0 represents H or OH; R1 represents alkoxy; U and W represent N, V represents CH and R2 represents H or F, or U and V represent CH, W represents N and R2 /su
-
Page/Page column 37
(2010/03/02)
4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES
The invention relates to compounds of formula (I) wherein R0 represents H or OH; R1 represents alkoxy; U and W represent N, V represents CH and R2 represents H or F, or U and V represent CH, W represents N and R2/sup
-
Page/Page column 95
(2008/12/06)
More Articles about upstream products of 5345-57-3